BiomX Inc.
$1.46
▲
10.91%
2026-04-21 08:50:00
www.biomx.com
ASE: PHGE
Explore BiomX Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.55 M
Current Price
$1.46
52W High / Low
$14.71 / $1.5
Stock P/E
—
Book Value
$-12.5
Dividend Yield
—
ROCE
-101.67%
ROE
-3.17%
Face Value
—
EPS
$-37.05
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
1.7
Debt / Equity
0.4
Current Ratio
0.87
Quick Ratio
2.48
Forward P/E
-0.22
Price / Sales
—
Enterprise Value
$20.3 M
EV / EBITDA
-0.72
EV / Revenue
—
Rating
None
Target Price
$304
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 2. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 3. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 4. | Nuvalent, Inc. | $107.99 | — | $8.48 B | — | -31.35% | -36.7% | $113.02 / $63.55 | $15.96 |
| 5. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 6. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 7. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -8.54 M | -7.43 M | -7.76 M | -8.51 M | -10.53 M |
| Net Profit | -9.17 M | -6.04 M | -7.66 M | -14.51 M | 9.64 M |
| EPS in Rs | -1.4 | -0.92 | -1.17 | -2.22 | 1.47 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -35.55 M | -25.35 M | -27.22 M | -35.46 M |
| Net Profit | -17.73 M | -26.17 M | -28.32 M | -36.23 M |
| EPS in Rs | -2.71 | -4 | -4.33 | -5.54 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 43.23 M | 25.03 M | 45.53 M | 77.99 M |
| Total Liabilities | 19.09 M | 21.95 M | 24.49 M | 30.45 M |
| Equity | 24.15 M | 3.08 M | 21.04 M | 47.53 M |
| Current Assets | 20.52 M | 17.63 M | 36.88 M | 66.64 M |
| Current Liabilities | 8.27 M | 11.18 M | 7.94 M | 11.04 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -36.98 M | -21.29 M | -29.09 M | -27.57 M |
| Investing CF | 0.71 M | 1.95 M | -2.11 M | 16.17 M |
| Financing CF | 38.37 M | 2.9 M | 0.29 M | 37.28 M |
| Free CF | -37.01 M | -21.34 M | -29.2 M | -31.25 M |
| Capex | -0.03 M | -0.05 M | -0.11 M | -3.68 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 32.26% | 7.59% | 21.83% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-11-25 | 1:0.0526316 |
| 2024-08-26 | 1:0.1 |